Milven (Venlafaxine)

Venlafaxine blocks the reuptake of serotonin and norepinephrine in the brain, raising their levels in the synaptic cleft. This dual‑action enhances neurotransmission in pathways that regulate mood and anxiety, helping to alleviate depressive symptoms and reduce excessive worry.

The appropriate dose of venlafaxine is individualized. The prescribing clinician determines the starting dose, titration schedule, and any adjustments based on the patient’s condition, response, tolerability, and relevant clinical guidelines. No fixed regimen is provided here.

Safety of venlafaxine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and discuss them with the patient. If treatment is necessary, close monitoring is recommended.

To request Milven, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Milven (venlafaxine) is an SNRI, offering both serotonergic and noradrenergic activity, whereas many alternatives such as selective serotonin reuptake inhibitors (SSRIs) primarily affect serotonin alone. This broader mechanism can provide additional benefit for patients who do not respond adequately to SSRIs, but it may also be associated with a different side‑effect profile.

Milven should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Milven is taken orally, usually with or without food, as directed by a healthcare professional. The tablets are swallowed whole with a glass of water and should be taken at the same time each day to maintain consistent blood levels.

Serious risks include the emergence of suicidal thoughts or behaviors, especially in young adults, serotonin syndrome when combined with other serotonergic agents, severe hypertension, hyponatremia, and rare cases of hepatic injury. Patients should be monitored closely for any of these signs.

Milven is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to venlafaxine, and individuals with uncontrolled severe hypertension. Caution is also advised for patients with bipolar disorder, liver impairment, or a history of seizures.